Overview
Liraglutide is an FDA-approved GLP-1 receptor agonist, prescribed as Victoza (type 2 diabetes) and Saxenda (weight management). It's the once-daily predecessor to weekly agents like semaglutide.
How It's Thought to Work
Like other GLP-1 agonists, it stimulates insulin release, slows gastric emptying, and reduces appetite.
What the Research Says
Backed by large human clinical trial programs (LEAD for diabetes, SCALE for obesity) and cardiovascular outcome data.
Regulatory & Legal Status
FDA-approved and prescription-only. Compounded/counterfeit versions are a safety concern.
Safety Considerations
Common GI side effects; important warnings and contraindications apply. Use only under a prescribing clinician.